T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
Open accessThe DOI matches its Crossref record; 62 of the 64 references it cites were found in a registry or an index.
Abstract
In diffuse large B-cell lymphoma (DLBCL), the number of circulating monocytes and neutrophils represents an independent prognostic factor. These cell subsets include monocytic and granulocytic myeloid-derived suppressor cells (M- and G-MDSCs) defined by their ability to suppress T-cell responses. MDSCs are a heterogeneous population described in inflammatory and infectious diseases and in numerous tumors including multiple myeloma, chronic lymphocytic leukemia, and DLBCL. However, their mechanisms of action remain unclear. We broadly assessed the presence and mechanisms of suppression of MDSC subsets in DLBCL. First, a myeloid suppressive signature was identified by gene expression profiling in DLBCL peripheral blood. Accordingly, we identified, in a cohort of 66 DLBCL patients, an increase in circulating G-MDSC (Lin(neg)HLA-DR(neg)CD33(pos)CD11b(pos)) and M-MDSC (CD14(pos)HLA-DR(low)) counts. Interestingly, only M-MDSC number was correlated with the International Prognostic Index, event-free survival, and number of circulating Tregs. Furthermore, T-cell proliferation was restored after monocyte depletion. Myeloid-dependent T-cell suppression was attributed to a release of interleukin-10 and S100A12 and increased PD-L1 expression. In summary, we identified expanded MDSC subsets in DLBCL, as well as new mechanisms of immunosuppression in DLBCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“patients with lymphoma have high levels of circulating myeloid-derived suppressor cells (MDSCs) compared with healthy control subjects”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in LBCL, a higher number of CD14+, HLA-DRlow monocytic (M)-MDSCs associate with higher risk disease and poorer efficacy after chemotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [20]
Experimental — accuracy not yet measuredIn the citing paper
“M-MDSCs are elevated in patients with LBCL compared with healthy control subjects and associate with decreased efficacy of standard chemo-immunotherapy.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“edu/gsea/) on theDLBCLdataset using a panel of genes that we defined as related to myeloid suppressive cells based on literature knowledge (supplemental Table 1, available on the BloodWeb site).(30)”
MethodWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A., Boldrick, J. C., Sabet, H., Tran, T., Yu, X., et al. (2000) · Nature · doi:10.1038/35000501 · Cited by 9,925
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 9×
“Various additional markers (including CD116, CD124, vascular endothelial growth factor receptor [VEGFR], CD11c, CD11b, and CD274) have been associated with MDSCs.(19) Interestingly, these markers are likely regulated through various stimuli, depending on the tumor type.”
BackgroundInfluentialA Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
WHO classification of haematolymphoid tumours
Gaillard, F., Weerakkody, Y., & Sharma, R. (2010) · Radiopaedia.org · doi:10.53347/rid-9250 · Cited by 3,776
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 3×
“Because of the lack of correlation betweenM-MDSCs and arginase1or IDO in DLBCL, we sought for additional mechanisms of immunosuppression already described for MDSCs, including Treg induction, IL-10 and TGFb release, and PD-L1 expression.(21) First, we found that Treg andM-MDSCcountswere correlated inDLBCLpatients (r5…”
BackgroundNomenclature of monocytes and dendritic cells in blood
Ziegler-Heitbrock, L., Ancuta, P., Crowe, S., Dalod, M., Grau, V., Hart, D. N., Leenen, P. J. M., Liu, Y.-J., MacPherson, G., Randolph, G. J., et al. (2010) · Blood · doi:10.1182/blood-2010-02-258558 · Cited by 2,436 · cited 1×
“As the myeloid regulatory compartment in peripheral blood also includes dendritic cells, we assessed the 3 subsets of dendritic cells as follows: LinHLA-DRCD123CD141CD1c pDC, LinHLA-DRCD123CD141CD1c type 1 cDCs and LinHLA-DRCD123CD141CD1c type 2 cDCs.(35) These cell types were significantly decreased in DLBCL compared…”
BackgroundStromal Gene Signatures in Large-B-Cell Lymphomas
Lenz, G., Wright, G., Dave, S. S., Xiao, W., Powell, J., Zhao, H., Xu, W., Tan, B., Goldschmidt, N., Iqbal, J., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802885 · Cited by 1,808
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530 · cited 1×
“It would be interesting to monitor these populations during the course of the treatment; indeed, accumulation or depletion of MDSCs is influenced by chemotherapy and/or immunotherapy.(59) Our study also points out the potential interest of MDSCs as targets in future therapeutic trials on DLBCL patients.”
Background
Cited by
Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Strauss, L., Mahmoud, M. A. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., Pal, R., Yuan, M., Asara, J., Patsoukis, N., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aay1863 · Cited by 437
The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy
Li, G., Tian, Y., & Zhu, W.-G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576946 · Cited by 352
Jain, M. D., Zhao, H., Wang, X., Atkins, R., Menges, M., Reid, K., Spitler, K., Faramand, R., Bachmeier, C., Dean, E. A., et al. (2021) · Blood · doi:10.1182/blood.2020007445 · Cited by 297
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
Yeo, A. T., Rawal, S., Delcuze, B., Christofides, A., Atayde, A., Strauss, L., Balaj, L., Rogers, V. A., Uhlmann, E. J., Varma, H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01215-0 · Cited by 290
Yang, Y., Li, C., Liu, T., Dai, X., & Bazhin, A. V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01371 · Cited by 291
Metadata
- Authors
- Azzaoui, I., Uhel, F., Rossille, D., Pangault, C., Dulong, J., Le Priol, J., Lamy, T., Houot, R., Le Gouill, S., Cartron, G., Godmer, P., Bouabdallah, K., Milpied, N., Damaj, G., Tarte, K., Fest, T., & Roussel, M.
- Affiliations
- Pôle Biologie and
- Inserm (FR)
- Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Nantes, Unité Mixte de Recherche 892 équipe 10, Nantes, France;
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre hospitalier Bretagne Atlantique (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2016-08-25
- Volume
- 128
- Issue
- 8
- Pages
- 1081-1092
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2470898142
- Cited by
- 168
- References
- 64
- Citations by year
- 2026: 6 · 2025: 19 · 2024: 19 · 2023: 7 · 2022: 22 · 2021: 26 · 2020: 24 · 2019: 8 · 2018: 16 · 2017: 19 · 2016: 2
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Funders
- Institut National de la Santé et de la Recherche Médicale
- Institut National Du Cancer
- Université de Montpellier
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Keywords
- diffuse large B-cell lymphoma, myeloid-derived suppressor cells, T cell suppression, granulocytic MDSCs, immunosuppression, IL-10, S100A12, PD-L1, regulatory T cells, International Prognostic Index, prognostic factors, T cell proliferation
- MeSH terms
- S100A12 Protein, Myeloid-Derived Suppressor Cells, Arginase, Humans, Immunosuppression Therapy, Monocytes, T-Lymphocytes, Gene Expression Regulation, Neoplastic, Lymphoma, Large B-Cell, Diffuse, Interleukin-10, Gene Expression Profiling, Cell Proliferation, Indoleamine-Pyrrole 2,3,-Dioxygenase, Transcriptome, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. https://app.cochat.ai/papers/10.1182/blood-2015-08-662783
- The paper
- Azzaoui, I., Uhel, F., Rossille, D., Pangault, C., Dulong, J., Le Priol, J., Lamy, T., Houot, R., Le Gouill, S., Cartron, G., Godmer, P., Bouabdallah, K., Milpied, N., Damaj, G., Tarte, K., Fest, T., & Roussel, M. (2016). T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood. https://doi.org/10.1182/blood-2015-08-662783
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.